ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

ClinicalTrials.gov ID: NCT06841055

Public ClinicalTrials.gov record NCT06841055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 11:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)

Study identification

NCT ID
NCT06841055
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
BioNTech SE
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • Pumitamig Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2, 2025
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028
Last update posted
Apr 23, 2026

2025 – 2028

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
The University of Alabama at Birmingham Hospital Birmingham Alabama 35249 Recruiting
Moffitt Cancer Center Tampa Florida 33612 Recruiting
Baptist Health Hardin Elizabethtown Kentucky 42701 Recruiting
NYU Langone - NYU Grossman School of Medicine New York New York 10016 Recruiting
Texas Oncology, P.A. Houston Texas 77090 Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06841055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 23, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06841055 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →